In vivo and in vitro studies have demonstrated that HIF-1 inhibitors reduce the survival and growth of CML cells and decrease the sustenance of LSCs, but without serious effects on non-CML hematopoietic cells (126). This evidence concerns the gene HIF1A and chronic myelogenous leukemia, BCR-ABL1 positive.